Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:A
NYSE:ALife Sciences

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

In February 2026, Agilent Technologies reported first-quarter 2026 sales of US$1,798 million, with net income of US$305 million, and raised full-year 2026 revenue guidance to a range of US$7.30 billion to US$7.50 billion while issuing new second-quarter revenue guidance of US$1,790 million to US$1,820 million. Management’s decision to increase full-year revenue guidance while first-quarter earnings per share were slightly lower than a year earlier highlights confidence in cost control and...
NYSE:CCI
NYSE:CCISpecialized REITs

Assessing Crown Castle (CCI) Valuation After Earnings Beat Guidance And Planned Fiber Divestiture

Crown Castle (CCI) has been back in focus after fourth quarter 2025 results topped analyst estimates, followed by 2026 guidance and plans to sell its small cell and fiber businesses later this year. See our latest analysis for Crown Castle. The recent earnings beat, new 2026 guidance and the plan to sell the small cell and fiber businesses have coincided with an 11.81% 1-month share price return from Crown Castle, even though the 1-year total shareholder return of a 2.70% decline and 5-year...
SEHK:388
SEHK:388Capital Markets

A Look At Hong Kong Exchanges And Clearing (SEHK:388) Valuation After Strong Earnings And Higher Second Interim Dividend

Earnings and dividend decisions put Hong Kong Exchanges and Clearing (SEHK:388) in focus Hong Kong Exchanges and Clearing (SEHK:388) is on investors’ radar after reporting full year 2025 results with revenue of HK$29,161 million and net income of HK$17,754 million, alongside a higher second interim dividend of HK$6.52 per share. See our latest analysis for Hong Kong Exchanges and Clearing. The latest earnings, higher second interim dividend and upcoming board refresh arrive as the shares...
NYSE:PRI
NYSE:PRIInsurance

Primerica (PRI) Valuation Check After Recent Share Price Weakness And Long Term Return Strength

Primerica stock reaction and recent performance snapshot Primerica (PRI) shares recently closed at US$257.31. The stock has seen mixed returns, with a 2.6% decline over the past day, a 6.7% decline over the past month, and a modest gain over the past 3 months. See our latest analysis for Primerica. While the 1-day share price return of 2.6% and 30-day share price return of 6.7% declines point to fading short term momentum, the 3-year total shareholder return of 59.38% and 5-year total...
NYSE:AGCO
NYSE:AGCOMachinery

Do AGCO’s (AGCO) New Board Move and Tariff Outlook Recast Its Margin Resilience Story?

In recent days, AGCO Corporation appointed former Corteva Agriscience CEO James C. Collins, Jr. to its Board of Directors, while also updating its annual incentive plan and highlighting significant expected 2026 tariff costs of about US$105 million to US$110 million at a major investor conference. This combination of governance changes, technology-focused initiatives, and tariff-related headwinds gives investors fresh information on how AGCO is balancing growth ambitions with cost and risk...
NYSE:HUM
NYSE:HUMHealthcare

Humana (HUM) Valuation Check As US$1b Junior Subordinated Notes Offering Draws Investor Attention

Humana (HUM) is in focus after pricing a US$1 billion junior subordinated notes offering due 2056. The notes received a stable credit rating from AM Best, drawing attention to the stock’s capital structure. See our latest analysis for Humana. Despite fresh headlines around the junior subordinated notes and new value based cardiac care partnerships, Humana’s 30 day share price return of 7.63% and year to date share price return of 32.26% highlight ongoing pressure. This is also reflected in a...
TSX:ENB
TSX:ENBOil and Gas

Will Enbridge’s (TSX:ENB) New CA$2 Billion Bond Deals and Dividend Hike Change Its Narrative

In February 2026, Enbridge Inc. completed three fixed-income offerings totaling about CA$2.00 billion across 2026, 2031, and 2056 unsecured, unsubordinated guaranteed notes with fixed coupons ranging from 3.57% to 5.10%. These bond issues, alongside Enbridge’s recently reported record 2025 financial performance and multi-decade dividend growth streak, highlight how the company continues funding long-term infrastructure while prioritizing consistent shareholder payouts. Next, we’ll examine...
NYSE:WU
NYSE:WUDiversified Financial

Is Western Union’s USDPT Stablecoin Rollout Reshaping The Investment Case For Western Union (WU)?

Earlier this month, Crossmint announced it is partnering with Western Union to support the rollout of USDPT, a U.S. dollar-denominated stablecoin issued on Solana, and to integrate with Western Union’s new Digital Asset Network that connects digital dollars to cash access at more than 360,000 collection points worldwide. This move is distinctive because it links on-chain stablecoin transfers directly to Western Union’s global cash payout infrastructure, potentially making digital dollars far...
OB:AFG
OB:AFGConstruction

AF Gruppen (OB:AFG) Valuation Check After New North Sea Contract And Zero Emission Project Progress

AF Gruppen (OB:AFG) is in focus after securing a consortium contract to engineer and decommission a large North Sea platform, while also progressing a zero-emission facility in Drammen that highlights its environmental services ambition. See our latest analysis for AF Gruppen. Despite the latest contract win and progress on the zero-emission facility, AF Gruppen’s share price sits at NOK182.4, with a 1 month share price return showing a 3.2% decline, while the 1 year total shareholder return...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)?

In March 2026, Takeda and Protagonist Therapeutics announced that the FDA had accepted and granted Priority Review to their New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for adults with polycythemia vera, with a PDUFA target action date in the third quarter of this year. This filing, backed by Phase 3 VERIFY and long-term Phase 2 REVIVE and THRIVE data and multiple expedited regulatory designations, positions rusfertide as a potential new option for improving...
NasdaqCM:MOBX
NasdaqCM:MOBXSemiconductor

Mobix Labs (MOBX) Is Up 530.3% After New Defense-Aerospace Orders and Quorum Shift - Has The Bull Case Changed?

In early March 2026, Mobix Labs, Inc. reported new production purchase orders for its high-reliability electromagnetic interference protection components used in Gulfstream business jets and the U.S. Navy’s Tomahawk cruise missile program, alongside a change to its bylaws reducing the shareholder meeting quorum requirement to one-third of voting power. The fresh aerospace and defense orders underline Mobix Labs’ role as an already-qualified supplier embedded in mission-critical platforms...
TSE:9143
TSE:9143Logistics

A Look At SG Holdings (TSE:9143) Valuation After Fresh Earnings Guidance For Fiscal 2027

SG Holdings Ltd (TSE:9143) drew investor focus after issuing earnings guidance for the fiscal year ending March 31, 2027, along with announcing a board meeting to consider its business plan for that period. See our latest analysis for SG HoldingsLtd. The latest earnings guidance and business plan review arrive after a mixed price pattern, with a 1 day share price return of 1.17%, a 7 day share price return of 7.47%, and a 1 year total shareholder return of 7.09%, suggesting momentum has been...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

Does Booking Holdings (BKNG) Offer Value After Recent Share Price Weakness

Before we get into the numbers, if you are wondering whether Booking Holdings is priced attractively today, this article will walk through what the current market price might be implying about its value. Over the very short term the stock has been mixed, with a 7.3% return over the last 7 days and 2.1% over the last 30 days, while year to date the share price shows a 14.5% decline and a 1.9% decline over the last year. This is set against longer term returns of 86.9% over 3 years and 93.1%...
BIT:BMPS
BIT:BMPSBanks

A Look At Banca Monte dei Paschi Di Siena (BIT:BMPS) Valuation After Recent Share Price Weakness

Recent share performance and business snapshot Banca Monte dei Paschi di Siena (BIT:BMPS) has seen recent pressure on its share price, with a 2.7% decline over the past day and negative returns over the past week, month, and past 3 months. For context, the bank reports annual revenue of €4,560.9m and net income of €2,715.7m, alongside a value score of 5. This gives investors a starting point to compare its current share performance with underlying business results. See our latest analysis for...
ASX:XRO
ASX:XROSoftware

Is Sector Rotation Forcing Xero (ASX:XRO) To Rethink Its High-Valuation Growth Playbook?

A leading analyst recently issued a sell recommendation on Xero, arguing that sector rotation away from high P/E technology stocks is putting pressure on the company despite its recent rebound. This call highlights how sentiment toward high-valuation software names can quickly shift, even as Xero continues to invest in new products and growth initiatives. We’ll now explore how this bearish analyst view, anchored on rotation away from high P/E tech, may affect Xero’s investment...
TSX:MX
TSX:MXChemicals

Assessing Methanex (TSX:MX) Valuation After A Sharp One Day Share Price Decline

Recent share performance and what it might signal Methanex (TSX:MX) has drawn attention after a recent 13.4% one day share price decline, prompting investors to reassess how its current valuation lines up with its fundamentals and recent performance indicators. See our latest analysis for Methanex. That sharp 13.4% one day share price decline comes after a solid run, with a 30 day share price return of 4.7%, a 90 day gain of 28.41% and a year to date rise of 20.65%. The 1 year total...
TSX:BITF
TSX:BITFSoftware

Bitfarms’ (TSX:BITF) U.S. Move and Rebrand: Strategic Upgrade or Risky Identity Shift?

Bitfarms recently secured backing from leading proxy advisory firms, including Institutional Shareholder Services, for its now-past March 20, 2026 shareholder vote on redomiciling to the U.S. and rebranding as Keel Infrastructure, with plans for the new entity to trade as “KEEL” on Nasdaq and TSX. This endorsement supports Bitfarms’ effort to reposition from a Canadian Bitcoin miner to a U.S.-domiciled HPC and AI infrastructure company, potentially enhancing its access to U.S. capital and...
NYSE:MCY
NYSE:MCYInsurance

Assessing Mercury General (MCY) Valuation After Strong 1 Year Return And Recent Pullback

What Mercury General’s Recent Performance Tells You Mercury General (MCY) has attracted fresh attention after a strong 1 year total return of 71.35%, alongside mixed shorter term moves, including a month decline of about 4.95% and a modest gain over the past 3 months. See our latest analysis for Mercury General. The recent pullback, including a 1 month share price return of about a 5% decline from a last close of US$90.48, sits against a much stronger 1 year total shareholder return of...
NYSE:NIQ
NYSE:NIQMedia

A Look At NIQ Global Intelligence (NIQ) Valuation After Recent Share Price Swings

NIQ Global Intelligence: Recent Price Moves and Business Snapshot NIQ Global Intelligence (NIQ) has drawn fresh attention after recent share price swings, with the stock down 2.5% over the past day, weaker over the past week, but positive over the past month. For investors looking at the consumer data and analytics space, NIQ sits in an interesting position. The company reports annual revenue of US$4,198.4m and a net loss of US$353.3m, while its value score stands at 6. Over the past 3...
NYSE:RXO
NYSE:RXOTransportation

Assessing RXO (RXO) Valuation After Rising Transport Costs And Institutional Share Reductions

RXO (RXO) stock has been under pressure after reports of rising transportation costs and large share reductions by some institutional holders, which have sharpened investor focus on margin resilience and balance sheet strength. See our latest analysis for RXO. RXO’s recent selloff, including a 1 day share price return of 11.07% decline and a 7 day share price return of 13.91% decline to US$13.74, comes after months of softer results. The 1 year total shareholder return of 30.64% decline shows...
NYSE:ENVA
NYSE:ENVAConsumer Finance

Assessing Enova International (ENVA) Valuation After Weak February U.S. Jobs Surprise

The weak February U.S. jobs report, which showed a loss of 92,000 jobs and unemployment at 4.4%, triggered a 3.6% drop in Enova International (ENVA), highlighting investor concern around credit conditions and demand. See our latest analysis for Enova International. That jobs-driven drop comes after a tougher few weeks for the share price, with a 30 day share price return of a 14.6% decline and a year to date share price return of a 15.05% decline, even though the 1 year total shareholder...
NYSE:CBT
NYSE:CBTChemicals

Cabot (CBT) Valuation After EPS Beat And Lower 2026 Outlook For Reinforcement Materials

Cabot (CBT) is back in focus after first quarter fiscal 2026 results that beat earnings estimates, but came with lower year over year sales and a trimmed adjusted EPS outlook. See our latest analysis for Cabot. The earnings beat has not stopped selling pressure in the short term, with a 1 day share price return of 5.40% decline and a 7 day share price return of 8.04% decline. At the same time, the 90 day share price return of 8.49% and 5 year total shareholder return of 46.88% point to a...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials

Septerna, Inc. recently reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing favorable tolerability, once-daily pharmacokinetics and clinical proof-of-mechanism in humans. The company’s decision to move SEP-631 into a Phase 2b trial for chronic spontaneous urticaria, alongside an open-label study in chronic inducible urticaria, highlights a focused push into difficult-to-treat allergic skin conditions. We will now examine how SEP-631’s...
ASX:PNI
ASX:PNICapital Markets

The Bull Case For Pinnacle Investment Management Group (ASX:PNI) Could Change Following Index Exit Amid Rising FUM

S&P Dow Jones Indices has announced that Pinnacle Investment Management Group will be removed from the S&P/ASX 100 Index at the March 2026 quarterly rebalance, while the company has also issued new shares and options under its employee incentive schemes and reported higher funds under management and net inflows. This combination of index exclusion and ongoing business growth, including A$17.20 billion in net inflows and funds under management reaching A$202.50 billion, highlights a contrast...